Expression vectors for human adenosine deaminase gene therapy.

Area of Science:

• Biotechnology
• Gene Therapy
• Hematology

Background:

• Somatic gene transfer presents a novel therapeutic strategy for genetic disorders.
• Hematopoietic stem cells are key targets for gene therapy due to their role in blood formation.
• Adenosine deaminase (ADA) deficiency serves as a model for developing and testing gene transfer techniques.

Purpose of the Study:

• To construct and evaluate retroviral vectors for efficient transfer and expression of human ADA.
• To assess the in vitro and in vivo efficacy of gene transfer in hematopoietic stem cells.
• To establish a model for studying gene transfer efficiency, expression regulation, and long-term stability.

Main Methods:

• Development and testing of 20 retroviral vectors for human ADA gene transfer.
• Infection of primary bone marrow cells with selected retroviral vectors.
• Assessment of gene transfer and expression in a mouse bone marrow transplantation model.

Main Results:

• One vector (p delta NN2ADA) demonstrated successful transfer and expression of human ADA in hematopoietic cells.
• Human ADA was detected in 60-85% of spleen colonies at 14 days post-transplantation.
• Sustained long-term expression of human ADA was observed in the blood of reconstituted mice.

Conclusions:

• Retroviral vector-mediated gene transfer is effective for delivering functional ADA to hematopoietic stem cells.
• The developed mouse model facilitates evaluation of gene transfer efficiency and expression stability.
• This system supports further research into optimizing gene therapy for genetic blood disorders.